The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Correcting glucose-6-phosphate dehydrogenase deficiency with a small-molecule activator
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency, one of the most common human genetic enzymopathies, is caused by over 160 different point mutations and contributes to the severity of many acute and chronic diseases associated with oxidative stress, including hemolytic anemia and bilirubin-induced neurological damage particularly in newborns. As no medications are available to treat G6PD deficiency, here we seek to identify a small molecule that corrects it. Crystallographic study and mutagenesis analysis identify the structural and functional defect of one common mutant (Canton, R459L). Using high-throughput screening, we subsequently identify AG1, a small molecule that increases the activity of the wild-type, the Canton mutant and several other common G6PD mutants. AG1 reduces oxidative stress in cells and zebrafish. Furthermore, AG1 decreases chloroquine- or diamide-induced oxidative stress in human erythrocytes. Our study suggests that a pharmacological agent, of which AG1 may be a lead, will likely alleviate the challenges associated with G6PD deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike other cells, RBCs cannot produce NADPH by an alternative pathway because they lack functional mitochondria”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Hwang et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cappadoro, M., Giribaldi, G., O'Brien, E., Turrini, F., Mannu, F., Ulliers, D., Simula, G., Luzzatto, L., & Arese, P. (1998) · Blood · doi:10.1182/blood.v92.7.2527 · Cited by 339
Research works printed but not linked: 64
- Minucci, A. et al. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the “old” and update of the new mutations. Blood Cells Mol. Dis. 48, 154–165 (2012). · doi:10.1016/j.bcmd.2012.01.001
- Beutler, E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood 111, 16–24 (2008). · DOI · Paper page
- Belfield K. D., Tichy E. M. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. Am. J. Health Syst. Pharm. 75, 97–104 (2018). · DOI
- Cappellini, M. D. & Fiorelli, G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 371, 64–74 (2008). · DOI · Paper page
- Nkhoma, E. T., Poole, C., Vannappagari, V., Hall, S. A. & Beutler, E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol. Dis. 42, 267–278 (2009). · DOI · Paper page
- Luzzatto, L. & Arese, P. Favism and Glucose-6-phosphate dehydrogenase deficiency. N. Engl. J. Med 378, 60–71 (2018). · DOI · Paper page
- Luzzatto, L. & Seneca, E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br. J. Haematol. 164, 469–480 (2014). · DOI · Paper page
- Baird, K. Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivaxmalaria. Pathog. Glob. Health 109, 93–106 (2015). · DOI
- Kaplan, M. & Hammerman, C. Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus. Semin. Perinatol. 28, 356–364 (2004). · doi:10.1053/j.semperi.2004.09.001
- Kaplan, M. et al. Bilirubin conjugation, reflected by conjugated bilirubin fractions, in glucose-6-phosphate dehydrogenase-deficient neonates: a determining factor in the pathogenesis of hyperbilirubinemia. Pediatrics 102, E37 (1998). · DOI
- Kaplan, M., Hammerman, C. & Bhutani, V. K. The preterm infant: a high-risk situation for neonatal hyperbilirubinemia due to glucose-6-phosphate dehydrogenase deficiency. Clin. Perinatol. 43, 325–340 (2016). · doi:10.1016/j.clp.2016.01.008
- Johnson, L., Bhutani, V. K., Karp, K., Sivieri, E. M. & Shapiro, S. M. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J. Perinatol. 29, S25–S45 (2009). · DOI · Paper page
- Diamond, I., Odell, G. B., Johnson, L., Boggs, T. R. & Lucey, J. F. Kernicterus: revised concepts of pathogenesis and management. Pediatrics 38, 539–546 (1966). · doi:10.1542/peds.38.4.539
- Cunningham, A. D., Hwang, S. & Mochly-Rosen, D. Glucose-6-phosphate dehydrogenase deficiency and the need for a novel treatment to prevent kernicterus. Clin. Perinatol. 43, 341–354 (2016). · DOI
- Chen, L. et al. Data mining and pathway analysis of glucose-6-phosphate dehydrogenase with natural language processing. Mol. Med. Rep. 16, 1900–1910 (2017). · DOI
- Spielberg, S. P., Boxer, L. A., Corash, L. M. & Schulman, J. D. Improved erythrocyte survival with high-dose vitamin E in chronic hemolyzing G6PD and glutathione synthetase deficiencies. Ann. Intern. Med. 90, 53–54 (1979). · doi:10.7326/0003-4819-90-1-53
- Newman, J. G., Newman, T. B., Bowie, L. J. & Mendelsohn, J. An examination of the role of vitamin E in glucose-6-phosphate dehydrogenase deficiency. Clin. Biochem. 12, 149–151 (1979). · doi:10.1016/s0009-9120(79)80078-8
- Johnson, G. J., Vatassery, G. T., Finkel, B. & Allen, D. W. High-dose vitamin E does not decrease the rate of chronic hemolysis in glucose-6-phosphate dehydrogenase deficiency. N. Engl. J. Med. 308, 1014–1017 (1983). · doi:10.1056/nejm198304283081708
- Schwartz, A. G. & Pashko, L. L. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res. Rev. 3, 171–187 (2004). · DOI
- Fang, Z. et al. Effects of G6PD activity inhibition on the viability, ROS generation and mechanical properties of cervical cancer cells. Biochim Biophys. Acta 1863, 2245–2254 (2016). · DOI
- Cohen, P. & Rosemeyer, M. A. Subunit interactions of glucose-6-phosphate dehydrogenase from human erythrocytes. Eur. J. Biochem. 8, 8–15 (1969). · doi:10.1111/j.1432-1033.1969.tb00488.x
- Kotaka, M. et al. Structural studies of glucose-6-phosphate and NADP+binding to human glucose-6-phosphate dehydrogenase. Acta Crystallogr. Sect. D Biol. Crystallogr. 61, 495–504 (2005). · DOI · Paper page
- Au, S. W., Gover, S., Lam, V. M. & Adams, M. J. Human glucose-6-phosphate dehydrogenase: the crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency. Structure 8, 293–303 (2000). · DOI · Paper page
- Cunningham, A. D., Colavin, A., Huang, K. C. & Mochly-Rosen, D. Coupling between protein stability and catalytic activity determines pathogenicity of G6PD variants. Cell Rep. 18, 2592–2599 (2017). · DOI
- Stevens, D. J., Wanachiwanawin, W., Mason, P. J., Vulliamy, T. J. & Luzzatto, L. G6PD Canton a common deficient variant in South East Asia caused by a 459 Arg–Leu mutation. Nucleic Acids Res. 18, 7190 (1990). · doi:10.1093/nar/18.23.7190
- Yang, Y. et al. Characterization of glucose-6-phosphate dehydrogenase deficiency and identification of a novel haplotype 487G>A/IVS5-612(G>C) in the Achang population of Southwestern China. Sci. China Ser. C. Life Sci. 50, 479–485 (2007). · doi:10.1007/s11427-007-0072-7
- Saha, N., Hong, S. H., Low, P. S. & Tay, J. S. Biochemical characteristics of four common molecular variants in glucose-6-phosphate dehydrogenase-deficient Chinese in Singapore. Hum. Hered. 45, 253–257 (1995). · doi:10.1159/000154308
- Wrigley, N. G., Heather, J. V., Bonsignore, A. & De Flora, A. Human erythrocyte glucose 6-phosphate dehydrogenase: electron microscope studies on structure and interconversion of tetramers, dimers and monomers. J. Mol. Biol. 68, 483–499 (1972). · doi:10.1016/0022-2836(72)90101-5
- Wang, X. T., Chan, T. F., Lam, V. M. & Engel, P. C. What is the role of the second “structural” NADP+-binding site in human glucose 6-phosphate dehydrogenase?. Protein Sci. 17, 1403–1411 (2008). · DOI
- Ahmad, S., Kumar, V., Ramanand, K. B. & Rao, N. M. Probing protein stability and proteolytic resistance by loop scanning: a comprehensive mutational analysis. Protein Sci. 21, 433–446 (2012).
- Roos, D. et al. Molecular basis and enzymatic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 94, 2955–2962 (1999).
- Vulliamy, T. et al. Independent origin of single and double mutations in the human glucose 6-phosphate dehydrogenase gene. Human. Mutat. 8, 311–318 (1996). · doi:10.1002/(sici)1098-1004(1996)8:4<311::aid-humu3>3.0.co;2-a
- Chen, H. L., Huang, M. J., Huang, C. S. & Tang, T. K. G6PD NanKang (517 T->C; 173 Phe->Leu): a new Chinese G6PD variant associated with neonatal jaundice. Human. Hered. 46, 201–204 (1996). · doi:10.1159/000154354
- Hebeisen, P. et al. Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. Bioorg. Med Chem. Lett. 18, 4708–4712 (2008). · DOI
- Gomez-Gallego, F., Garrido-Pertierra, A. & Bautista, J. M. Structural defects underlying protein dysfunction in human glucose-6-phosphate dehydrogenase A(−) deficiency. J. Biol. Chem. 275, 9256–9262 (2000). · doi:10.1074/jbc.275.13.9256
- Patrinostro, X., Carter, M. L., Kramer, A. C. & Lund, T. C. A model of glucose-6-phosphate dehydrogenase deficiency in the zebrafish. Exp. Hematol. 41, 697–710 (2013). · DOI
- Ho, R. K. & Kane, D. A. Cell-autonomous action of zebrafish spt-1 mutation in specific mesodermal precursors. Nature 348, 728–730 (1990). · DOI · Paper page
- Thompson, M. A. et al. The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. Dev. Biol. 197, 248–269 (1998). · DOI · Paper page
- Shimo, H. et al. Particle simulation of oxidation induced band 3 clustering in human erythrocytes. PLoS Comput. Biol. 11, e1004210 (2015). · DOI
- Garcia-Roa, M. et al. Red blood cell storage time and transfusion: current practice, concerns and future perspectives. Blood Transfus. 15, 222–231 (2017).
- Kucukakin, B. et al. Storage-induced increase in biomarkers of oxidative stress and inflammation in red blood cell components. Scand. J. Clin. Lab Invest 71, 299–303 (2011). · DOI
- Orlov, D. & Karkouti, K. The pathophysiology and consequences of red blood cell storage. Anaesthesia 70, 29–37 (2015). · DOI · Paper page
- Moro, F. et al. Glucose-6-phosphate dehydrogenase deficiency and incidence of cataract in Sicily. Ophthalmic Paediatr. Genet. 5, 197–200 (1985). · doi:10.3109/13816818509006134
- Meloni, T. et al. Increased prevalence of glucose-6-phosphate dehydrogenase deficiency in patients with cholelithiasis. Acta Haematol. 85, 76–78 (1991). · doi:10.1159/000204861
- Heymann, A. D., Cohen, Y. & Chodick, G. Glucose-6-phosphate dehydrogenase deficiency and type 2 diabetes. Diabetes Care 35, e58 (2012). · doi:10.2337/dc11-2527
- Niazi, G. A. Glucose-6-phosphate dehydrogenase deficiency and diabetes mellitus. Int. J. Hematol. 54, 295–298 (1991).
- Jeng, W., Loniewska, M. M. & Wells, P. G. Brain glucose-6-phosphate dehydrogenase protects against endogenous oxidative DNA damage and neurodegeneration in aged mice. ACS Chem. Neurosci. 4, 1123–1132 (2013). · DOI
- Bocchetta, A. Psychotic mania in glucose-6-phosphate-dehydrogenase-deficient subjects. Ann. Gen. Hosp. Psychiatry 2, 6 (2003). · doi:10.1186/1475-2832-2-6
- Hecker, P. A. et al. Glucose 6-phosphate dehydrogenase deficiency increases redox stress and moderately accelerates the development of heart failure. Circ. Heart Fail. 6, 118–126 (2013). · DOI
- Abdel Hakeem, G. L. et al. Detection of occult acute kidney injury in glucose-6-phosphate dehydrogenase deficiency anemia. Mediterr. J. Hematol. Infect. Dis. 8, e2016038 (2016). · doi:10.4084/mjhid.2016.038
- Nair, V. et al. Bilateral cataracts associated with glucose-6-phosphate dehydrogenase deficiency. J. Perinatol. 33, 574–575 (2013). · doi:10.1038/jp.2012.148
- Diamond, I. & Schmid, R. Neonatal hyperbilirubinemia and kernicterus. Experimental support for treatment by exposure to visible light. Arch. Neurol. 18, 699–702 (1968). · doi:10.1001/archneur.1968.00470360121012
- Diamond, I., Lucey, J. & Schmid, R. Prevention of hyperbilirubinemia and kernicterus by exposure to light: studies in newborn guinea pigs and premature infants. Trans. Am. Neurol. Assoc. 93, 70–74 (1968).
- Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bull. World Health Organ. 67, 601–611 (1989).
- Zorn, J. A. & Wells, J. A. Turning enzymes ON with small molecules. Nat. Chem. Biol. 6, 179–188 (2010). · DOI · Paper page
- Leslie, A. G. W. & Powell, H. R. Processing diffraction data with MOSFLM. Nato Sci. Ser. II-Math. 245, 41–51 (2007).
- Evans, P. Scaling and assessment of data quality. Acta Crystallogr. Sect. D Biol. Crystallogr. 62, 72–82 (2006). · DOI · Paper page
- Evans, P. R. An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr. Sect. D Biol. Crystallogr. 67, 282–292 (2011). · DOI · Paper page
- Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 2126–2132 (2004). · DOI · Paper page
- Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D Biol. Crystallogr. 53, 240–255 (1997). · DOI · Paper page
- Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. Sect. D Biol. Crystallogr. 67, 355–367 (2011). · DOI · Paper page
- Westerfield, M. The Zebrafish Book (University of Oregon Press, 1995).
- Montague, T. G., Cruz, J. M., Gagnon, J. A., Church, G. M. & Valen, E. CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res. 42, W401–W407 (2014). · DOI · Paper page
- Gagnon, J. A. et al. Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs. PLoS ONE 9, e98186 (2014). · DOI · Paper page
Cited by
The pentose phosphate pathway in health and disease
TeSlaa, T., Ralser, M., Fan, J., & Rabinowitz, J. D. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00863-2 · Cited by 650
Glucose-6-phosphate dehydrogenase deficiency
Luzzatto, L., Ally, M., & Notaro, R. (2020) · Blood · doi:10.1182/blood.2019000944 · Cited by 406
Jajosky, R. P., Wu, S.-C., Zheng, L., Jajosky, A. N., Jajosky, P. G., Josephson, C. D., Hollenhorst, M. A., Sackstein, R., Cummings, R. D., Arthur, C. M., et al. (2023) · iScience · doi:10.1016/j.isci.2022.105798 · Cited by 110
Acetylation-dependent coupling between G6PD activity and apoptotic signaling
(2023) · doi:10.1038/s41467-023-41895-2 · Cited by 28
Metadata
- Authors
- Hwang, S., Mruk, K., Rahighi, S., Raub, A. G., Chen, C.-H., Dorn, L. E., Horikoshi, N., Wakatsuki, S., Chen, J. K., & Mochly-Rosen, D.
- Venue
- Nature Communications
- Published
- 2018-10-02
- Volume
- 9
- Issue
- 1
- ISSN
- 2041-1723
- Cited by
- 111
- References
- 1
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD084422)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Correcting glucose-6-phosphate dehydrogenase deficiency with a small-molecule activator. https://app.cochat.ai/papers/10.1038/s41467-018-06447-z
- The paper
- Hwang, S., Mruk, K., Rahighi, S., Raub, A. G., Chen, C.-H., Dorn, L. E., Horikoshi, N., Wakatsuki, S., Chen, J. K., & Mochly-Rosen, D. (2018). Correcting glucose-6-phosphate dehydrogenase deficiency with a small-molecule activator. Nature Communications. https://doi.org/10.1038/s41467-018-06447-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.